Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Non Operating Income (2019 - 2022)

Goldenwell Biotech's Non Operating Income history spans 4 years, with the latest figure at $1.0 for Q2 2022.

  • For Q2 2022, Non Operating Income fell 99.62% year-over-year to $1.0; the TTM value through Mar 2023 reached $1.0, down 99.96%, while the annual FY2022 figure was $8.0, 99.38% down from the prior year.
  • Non Operating Income reached $1.0 in Q2 2022 per GWLL's latest filing, down from $7.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $1272.0 in Q3 2021 to a low of -$12.0 in Q4 2019.
  • Average Non Operating Income over 4 years is $334.9, with a median of $18.0 recorded in 2020.
  • Peak YoY movement for Non Operating Income: soared 25340.0% in 2021, then crashed 99.62% in 2022.
  • A 4-year view of Non Operating Income shows it stood at -$12.0 in 2019, then soared by 141.67% to $5.0 in 2020, then surged by 20460.0% to $1028.0 in 2021, then crashed by 99.9% to $1.0 in 2022.
  • Per Business Quant, the three most recent readings for GWLL's Non Operating Income are $1.0 (Q2 2022), $7.0 (Q1 2022), and $1028.0 (Q4 2021).